Tonix Pharmaceuticals Q2 Earnings Call Highlights

2 weeks ago 9

MarketBeat

Mon, August 10, 2026 astatine 11:04 AM CDT 6 min read

Key Points

Interested successful Tonix Pharmaceuticals Holding Corp.? Here are 5 stocks we similar better.
Tonmya drove beardown commercialized growth: Second-quarter nett merchandise gross reached astir $13.5 million, including $11 cardinal from Tonmya, whose income roseate 197% sequentially. Prescriptions doubled from the anterior quarter, supported by expanding refills and expanding payer coverage.
Tonix is expanding entree and its income force: Tonmya sum presently spans astir 136 cardinal U.S. lives, with sum expected to emergence to astir 145 cardinal by January 2027. The institution is adding 50 representatives, bringing its tract unit to astir 150.
Pipeline programs precocious amid higher spending: Tonix began its Phase II HORIZON proceedings of TNX-102 SL successful large depressive upset and plans to commencement a Phase II Lyme illness prevention survey of TNX-4800 successful aboriginal 2027. Cash totaled $176.2 cardinal astatine quarter-end, with backing expected to enactment operations into aboriginal Q2 2027.

Pharma Frenzy: Volatility Ignites Biotech Sector

Tonix Pharmaceuticals (NASDAQ:TNXP) reported second-quarter 2026 nett merchandise gross of astir $13.5 million, led by $11 cardinal successful income of fibromyalgia attraction Tonmya. The institution said Tonmya income roseate 197% from the archetypal quarter, its 2nd afloat 4th of commercialized income pursuing the product's November launch.

Revenue besides included astir $2.5 cardinal from migraine products Zembrace SymTouch and Tosymra, compared with $2 cardinal successful full merchandise gross successful the prior-year period, erstwhile gross consisted solely of the migraine products.

→ MarketBeat Week successful Review – 08/03 - 08/07

Is Tonix Pharmaceuticals the Next Biotech Breakout?

Chief Executive Officer Seth Lederman said the institution is pursuing commercialized enlargement for Tonmya portion prioritizing improvement of TNX-102 SL for large depressive upset and TNX-4800, a long-acting monoclonal antibody being developed to forestall Lyme disease.

Tonmya Sales and Access Expansion

Tonix said Tonmya, a once-daily, non-opioid analgesic taken astatine bedtime, is the archetypal FDA-approved medicine for big fibromyalgia successful much than 15 years. The institution said it is initially targeting astir 3 cardinal diagnosed and treated patients wrong an estimated U.S. big fibromyalgia colonisation of much than 10 million.

→ D-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-Off

During the 2nd quarter, prescriptions totaled 12,592, up 100% sequentially. New diligent prescriptions accrued 36% from the archetypal quarter, portion refills roseate 207%, according to Executive Vice President of Commercial Operations Thomas Englese.

Read Entire Article